Effects of generic competition in pharmaceuticals are more complex than they used to be Cost containment has been a major aspect of the Affordable Care Act (ACA), with incentives for…
The post Formulary Best Practice: Cost Containment through Generic D…
Formulary Best Practice: Cost Containment through Generic Drugs Read Post »
Market intelligence is especially critical to sound pharmaceutical investing Pharmaceutical investing is both challenging and potentially very rewarding, but it requires understanding trends in the industry, including which drugs are…
The post Pharmace…
Pharmaceutical Investments: Making the Case for Better Intelligence Read Post »
How are drugs named, and how do names aid in prescription and generic substitution? In William Shakespeare’s play Romeo and Juliet, Juliet uses the phrase “A rose by any other name…
The post A drug by any other name would work just as well — making sen…
A drug by any other name would work just as well — making sense of drug names Read Post »
This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for…
The post Biosimilar Naming: Distinguishable or Disingenuous? appeared first…
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »
How to Order the FDA Orange Book Historical copies of the FDA Orange Book archives are very potent tools for scholarly research and for litigation support, but until now there…
The post Download FDA Orange Book Archives appeared first on DrugPatentWatc…
Dana Goldman, Anupam Jena, Posted with permission from STAT It’s hard not to like the notion of value-based pricing for prescription drugs. It aims to ensure that the prices we pay for…
The post Value-based drug pricing makes sense, but is difficult to…
Value-based drug pricing makes sense, but is difficult to pull off Read Post »
One of the hottest-button political issues of the day is high prescription drug costs. On one side of the debate are politicians and patient groups espousing a populist viewpoint seeking…
The post The Cost Of A Cure: Patent Rights And Drug Prices appea…
The Cost Of A Cure: Patent Rights And Drug Prices Read Post »
Ed Silverman, Posted with permission from STAT Shortly before his company won the right last week to sell a new drug for severe eczema, Dr. Len Schleifer made a brash…
The post How a $37,000-a-year medicine sets a good model for drug pricing appeared f…
How a $37,000-a-year medicine sets a good model for drug pricing Read Post »
Rebecca Robbins, Posted with permission from STAT Plus When drug and device makers need a new chief medical officer or vice president, they often start by turning to executive recruiters. One…
The post Q&A: Three big mistakes drug companies make in rec…
Q&A: Three big mistakes drug companies make in recruiting new employees Read Post »
Damian Garde, Posted with permission from STAT Has the age of the biotech blockbuster come to a close? Over the past year, a string of would-be best-sellers, expected to generate…
The post As blockbuster drugs fizzle, biotech looks warily to the next b…
As blockbuster drugs fizzle, biotech looks warily to the next big thing Read Post »